Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug–Drug Interaction Studies
Open accessThe DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Abstract
Understanding transporter-mediated drug-drug interactions (DDIs) for investigational agents is important during drug development to assess DDI liability, its clinical relevance, and to determine appropriate DDI management strategies. P-glycoprotein (P-gp) is an efflux transporter that influences the pharmacokinetics (PK) of various compounds. Assessing transporter induction in vitro is challenging and is not always predictive of in vivo effects, and hence there is a need to consider clinical DDI studies; however, there is no clear guidance on when clinical evaluation of transporter induction is required. Furthermore, there is no proposed list of index transporter inducers to be used in clinical studies. This review evaluated DDI studies with known P-gp inducers to better understand the mechanism and site of P-gp induction, as well as the magnitude of induction effect on the exposure of P-gp substrates. Our review indicates that P-gp and cytochrome P450 (CYP450) enzymes are co-regulated via the pregnane xenobiotic receptor (PXR) and the constitutive androstane receptor (CAR). The magnitude of the decrease in substrate drug exposure by P-gp induction is generally less than that of CYP3A. Most P-gp inducers reduced total bioavailability with a minor impact on renal clearance, despite known expression of P-gp at the apical membrane of the kidney proximal tubules. Rifampin is the most potent P-gp inducer, resulting in an average reduction in substrate exposure ranging between 20 and 67%. For other inducers, the reduction in P-gp substrate exposure ranged from 12 to 42%. A lower reduction in exposure of the P-gp substrate was observed with a lower dose of the inducer and/or if the administration of the inducer and substrate was simultaneous, i.e. not staggered. These findings suggest that clinical evaluation of the impact of P-gp inducers on the PK of investigational agents that are substrates for P-gp might be warranted only for compounds with a relatively steep exposure-efficacy relationship.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Lehmann, J. M., McKee, D. D., Watson, M. A., Willson, T. M., Moore, J. T., & Kliewer, S. A. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3703 · Cited by 1,576
An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway
Kliewer, S. A., Moore, J. T., Wade, L., Staudinger, J. L., Watson, M. A., Jones, S. A., McKee, D. D., Oliver, B. B., Willson, T. M., Zetterström, R. H., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)80900-9 · Cited by 1,539
Role of P-Glycoprotein in Pharmacokinetics: Clinical Implications
Lin, J. H., & Yamazaki, M. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342010-00003 · Cited by 998
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.-P., von Richter, O., Zundler, J., & Kroemer, H. K. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6663 · Cited by 917
Nuclear Receptor Response Elements Mediate Induction of Intestinal MDR1 by Rifampin
Geick, A., Eichelbaum, M., & Burk, O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010173200 · Cited by 848
Kullak-Ublick, G. A., Ismair, M. G., Stieger, B., Landmann, L., Huber, R., Pizzagalli, F., Fattinger, K., Meier, P. J., & Hagenbuch, B. (2001) · Gastroenterology · doi:10.1053/gast.2001.21176 · Cited by 723
Goodwin, B., Hodgson, E., & Liddle, C. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12400-5 · Cited by 646
BDDCS Applied to Over 900 Drugs
Benet, L. Z., Broccatelli, F., & Oprea, T. I. (2011) · The AAPS Journal · doi:10.1208/s12248-011-9290-9 · Cited by 626
OATP and P-Glycoprotein Transporters Mediate the Cellular Uptake and Excretion of Fexofenadine
Cvetkovic, M., Leake, B., Fromm, M. F., Wilkinson, G. R., & Kim, R. B. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15235-x · Cited by 597
Importance of P-glycoprotein at blood–tissue barriers
Fromm, M. F. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.06.002 · Cited by 592
Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling
Huang, S.-M., Temple, R., Throckmorton, D. C., & Lesko, L. J. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100054 · Cited by 579
Balancing the strengths of systematic and narrative reviews
Collins, J. A., & Fauser, B. C. J. M. (2005) · Human Reproduction Update · doi:10.1093/humupd/dmh058 · Cited by 510
The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs
Shugarts, S., & Benet, L. Z. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9924-0 · Cited by 438
Ohtsuki, S., Schaefer, O., Kawakami, H., Inoue, T., Liehner, S., Saito, A., Ishiguro, N., Kishimoto, W., Ludwig-Schwellinger, E., Ebner, T., et al. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.042259 · Cited by 434
Stangier, J., Stähle, H., Rathgen, K., & Fuhr, R. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847010-00005 · Cited by 427
Clinical Pharmacokinetics of Rifampicin
Acocella, G. (1978) · Clinical Pharmacokinetics · doi:10.2165/00003088-197803020-00002 · Cited by 405
P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs
Fromm, M. F. (2000) · Int. Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp38069 · Cited by 399
Functional Characterization of pH-Sensitive Organic Anion Transporting Polypeptide OATP-B in Human
Nozawa, T., Imai, K., Nezu, J.-I., Tsuji, A., & Tamai, I. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.060194 · Cited by 351
Rostami-Hodjegan, A. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.65 · Cited by 331
MARSCHALL, H., WAGNER, M., ZOLLNER, G., FICKERT, P., DICZFALUSY, U., GUMHOLD, J., SILBERT, D., FUCHSBICHLER, A., BENTHIN, L., & GRUNDSTROM, R. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.05.009 · Cited by 325
Faucette, S. R., Zhang, T.-C., Moore, R., Sueyoshi, T., Omiecinski, C. J., LeCluyse, E. L., Negishi, M., & Wang, H. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.112136 · Cited by 294
Quercetin pharmacokinetics in humans
Moon, Y. J., Wang, L., DiCenzo, R., & Morris, M. E. (2008) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.605 · Cited by 287
Westphal, K. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.109797 · Cited by 285
Bertilsson, L., & Tomson, T. (1986) · Clinical Pharmacokinetics · doi:10.2165/00003088-198611030-00001 · Cited by 282
The Effect of Rifampin Treatment on Intestinal Expression of Human MRP Transporters
Fromm, M. F., Kauffmann, H.-M., Fritz, P., Burk, O., Kroemer, H. K., Warzok, R. W., Eichelbaum, M., Siegmund, W., & Schrenk, D. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64794-3 · Cited by 277
Clinical Pharmacokinetics of Digoxin
Iisalo, E. (1977) · Clinical Pharmacokinetics · doi:10.2165/00003088-197702010-00001 · Cited by 265
Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males
Zhang, W., Yu, B.-N., He, Y.-J., Fan, L., Li, Q., Liu, Z.-Q., Wang, A., Liu, Y.-L., Tan, Z.-R., Fen-Jiang, et al. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2006.05.010 · Cited by 263
Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects
Dresser, G. K., Schwarz, U. I., Wilkinson, G. R., & Kim, R. B. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2003.10 · Cited by 261
Role of P-Glycoprotein in Drug Disposition
Tanigawara, Y. (2000) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200002000-00029 · Cited by 261
Regulation of CYP3A4 Expression in Human Hepatocytes by Pharmaceuticals and Natural Products
Raucy, J. L. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.5.533 · Cited by 249
Role of CAR and PXR in xenobiotic sensing and metabolism
Wang, Y.-M., Ong, S. S., Chai, S. C., & Chen, T. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.685237 · Cited by 246
Chen, Y., Ferguson, S. S., Negishi, M., & Goldstein, J. A. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.058818 · Cited by 224
The effect of rifampin administration on the disposition of fexofenadine
Hamman, M. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113697 · Cited by 205
Ho, R. H., Choi, L., Lee, W., Mayo, G., Schwarz, U. I., Tirona, R. G., Bailey, D. G., Michael Stein, C., & Kim, R. B. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3280ef698f · Cited by 199
Shimizu, M., Fuse, K., Okudaira, K., Nishigaki, R., Maeda, K., Kusuhara, H., & Sugiyama, Y. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004622 · Cited by 183
Seward, D. J., Koh, A. S., Boyer, J. L., & Ballatori, N. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301106200 · Cited by 178
Tissue-specific mRNA Expression Profiles of Human Nuclear Receptor Subfamilies
Nishimura, M., Naito, S., & Yokoi, T. (2004) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.19.135 · Cited by 173
Li, L., Stanton, J. D., Tolson, A. H., Luo, Y., & Wang, H. (2009) · Pharmaceutical Research · doi:10.1007/s11095-008-9788-8 · Cited by 170
GIESSMANN, T., MAY, K., MODESS, C., WEGNER, D., HECKER, U., ZSCHIESCHE, M., DAZERT, P., GRUBE, M., SCHROEDER, E., & WARZOK, R. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.04.011 · Cited by 167
Backman, J. T., Olkkola, K. T., Ojala, M., Laaksovirta, H., & Neuvonen, P. J. (1996) · Epilepsia · doi:10.1111/j.1528-1157.1996.tb00021.x · Cited by 166
Effect of bioflavonoids on vincristine transport across blood–brain barrier
Mitsunaga, Y., Takanaga, H., Matsuo, H., Naito, M., Tsuruo, T., Ohtani, H., & Sawada, Y. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00180-1 · Cited by 161
Ahlin, G., Hilgendorf, C., Karlsson, J. E., Szigyarto, C. A., Uhlén, M., & Artursson, P. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.028654 · Cited by 160
Kusuhara, H., Furuie, H., Inano, A., Sunagawa, A., Yamada, S., Wu, C., Fukizawa, S., Morimoto, N., Ieiri, I., Morishita, M., et al. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01887.x · Cited by 159
Ferguson, S. S., LeCluyse, E. L., Negishi, M., & Goldstein, J. A. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.3.737 · Cited by 158
Reitman, M. L., Chu, X., Cai, X., Yabut, J., Venkatasubramanian, R., Zajic, S., Stone, J. A., Ding, Y., Witter, R., Gibson, C., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.271 · Cited by 156
Troutman, M. D., & Thakker, D. R. (2003) · Pharmaceutical Research · doi:10.1023/a:1025049014674 · Cited by 154
Molimard, M., Diquet, B., & Benedetti, M. S. (2004) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00254.x · Cited by 148
Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine
Oscarson, M., Zanger, U. M., Rifki, O. F., KLEIN, K., Eichelbaum, M. F., & Meyer, U. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.08.013 · Cited by 145
Gurley, B. J., Swain, A., Williams, D. K., Barone, G., & Battu, S. K. (2008) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200700081 · Cited by 143
Meyer zu Schwabedissen, H. E., Tirona, R. G., Yip, C. S., Ho, R. H., & Kim, R. B. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0265 · Cited by 138
Lethal quercetin-digoxin interaction in pigs
Wang, Y., Chao, P.-D. L., Hsiu, S., Wen, K., & Hou, Y. (2003) · Life Sciences · doi:10.1016/j.lfs.2003.06.044 · Cited by 133
Tahara, H., Kusuhara, H., Fuse, E., & Sugiyama, Y. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004192 · Cited by 131
Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin*1
MUELLER, S. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.01.014 · Cited by 130
Schwarz, U. I., Hanso, H., Oertel, R., Miehlke, S., Kuhlisch, E., Glaeser, H., Hitzl, M., Dresser, G. K., Kim, R. B., & Kirch, W. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100191 · Cited by 129
Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites
Patel, M., Taskar, K. S., & Zamek‐Gliszczynski, M. J. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.671 · Cited by 123
Kluth�, D., Banning, A., Paur, I., Blomhoff, R., & Brigelius‐Flohé, R. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.09.028 · Cited by 122
Clinical Implications of P-Glycoprotein Modulation in Drug–Drug Interactions
Lund, M., Petersen, T. S., & Dalhoff, K. (2017) · Drugs · doi:10.1007/s40265-017-0729-x · Cited by 121
Decrease in the oral bioavailability of dabigatran etexilate after co‐medication with rifampicin
Härtter, S., Koenen‐Bergmann, M., Sharma, A., Nehmiz, G., Lemke, U., Timmer, W., & Reilly, P. A. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04218.x · Cited by 120
Niemi, M., Arnold, K. A., Backman, J. T., Pasanen, M. K., Gödtel-Armbrust, U., Wojnowski, L., Zanger, U. M., Neuvonen, P. J., Eichelbaum, M., Kivistö, K. T., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230422.50962.91 · Cited by 109
Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid
Uçar, M., Neuvonen, M., Luurila, H., Dahlqvist, R., Neuvonen, P. J., & Mj�rndal, T. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0700-5 · Cited by 107
Clinical Pharmacokinetics of Digoxin 1980
Aronson, J. K. (1980) · Clinical Pharmacokinetics · doi:10.2165/00003088-198005020-00002 · Cited by 104
Matsushima, S., Maeda, K., Inoue, K., Ohta, K., Yuasa, H., Kondo, T., Nakayama, H., Horita, S., Kusuhara, H., & Sugiyama, Y. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023911 · Cited by 104
Coordinated induction of drug transporters and phase I and II metabolism in human liver slices
Olinga, P., Elferink, M. G. L., Draaisma, A. L., Merema, M. T., Castell, J. V., Pérez, G., & Groothuis, G. M. M. (2008) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.01.008 · Cited by 103
Zhang, W., & Lim, L. Y. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019737 · Cited by 99
Chrubasik‐Hausmann, S., Vlachojannis, J., & McLachlan, A. J. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12858 · Cited by 99
Amiodarone and thyroid function
Nademanee, K., Piwonka, R. W., Singh, B. N., & Hershman, J. M. (1989) · Progress in Cardiovascular Diseases · doi:10.1016/0033-0620(89)90017-0 · Cited by 97
Yu, C., Wu, P., Hou, Y., Lin, S.-P., Tsai, S.-Y., Chen, C., & Chao, P.-D. L. (2011) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf104786t · Cited by 95
Involvement of Multiple Efflux Transporters in Hepatic Disposition of Fexofenadine
Matsushima, S., Maeda, K., Hayashi, H., Debori, Y., Schinkel, A. H., Schuetz, J. D., Kusuhara, H., & Sugiyama, Y. (2008) · Molecular Pharmacology · doi:10.1124/mol.107.041459 · Cited by 93
Clinical Pharmacokinetics of Rifabutin
Skinner, M., & Blaschke, T. F. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199528020-00003 · Cited by 92
Magnusson, M. O., Dahl, M.-L., Cederberg, J., Karlsson, M., & Sandström, R. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100431 · Cited by 90
Hosey, C. M., Chan, R., & Benet, L. Z. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9845-2 · Cited by 86
Lutz, J. D., Kirby, B. J., Wang, L., Song, Q., Ling, J. R., Massetto, B., Worth, A., Kearney, B. P., & Mathias, A. A. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1073 · Cited by 85
ATP-dependent transport of statins by human and rat MRP2/Mrp2
Ellis, L. C. J., HAWKSWORTH, G. M., & Weaver, R. J. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.03.019 · Cited by 84
Taub, M. E., Mease, K. M., Sane, R. S., Watson, C. A., Chen, L.-F., Ellens, H. M., Hirakawa, B. P., Reyner, E. L., Jani, M., & Lee, C. A. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040816 · Cited by 84
Inhibition of the intestinal digoxin absorption and exsorption by quinidine.
Su, S. F., & Huang, J. D. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07290-3 · Cited by 82
Regulation of hepatic ABCC transporters by xenobiotics and in disease states
Gu, X., & Manautou, J. E. (2010) · Drug Metabolism Reviews · doi:10.3109/03602531003654915 · Cited by 81
Role of Glycosylation in Trafficking of Mrp2 in Sandwich-Cultured Rat Hepatocytes
Zhang, P., Tian, X., Chandra, P., & Brouwer, K. L. R. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.004481 · Cited by 81
Lutz, J. D., Kirby, B. J., Wang, L., Song, Q., Ling, J. R., Massetto, B., Worth, A., Kearney, B. P., & Mathias, A. A. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1072 · Cited by 79
Cheng, D., Li, W., Wang, L., Lin, T., Poiani, G. J., Wassef, A. M., Hudlikar, R. R., Ondar, P., Brunetti, L., & Kong, A. T. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01246 · Cited by 77
Reddy, D. R., Khurana, A., Bale, S., Ramu, R., Reddy, V. S. S., Mohankumar, M., & Godugu, C. (2016) · SpringerPlus · doi:10.1186/s40064-016-3267-1 · Cited by 76
Biliary excretion of digoxin in man
Caldwell, J. H., & Cline, C. T. (1976) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1976194410 · Cited by 73
Tubić-Grozdanis, M., Wagner, D., Spahn-Langguth, H., Bolger, M. B., & Langguth, P. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9020-7 · Cited by 70
Yamazaki, S., Costales, C., Lazzaro, S., Eatemadpour, S., Kimoto, E., & Varma, M. V. S. (2019) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12458 · Cited by 61
Pan, Y., Hsu, V., Grimstein, M., Zhang, L., Arya, V., Sinha, V. P., Grillo, J. A., & Zhao, P. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.740 · Cited by 56
Guo, C., LaCerte, C., Edwards, J. E., Brouwer, K. R., & Brouwer, K. L. R. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.246033 · Cited by 56
Self-citationMalinen, M. M., Ali, I., Tiley, J. B., Beaudoin, J. J., & Brouwer, K. L. R. (2018) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00310.2017 · Cited by 55
Kuhnz, W., Jäger‐Roman, E., Rating, D., Deichl, A., Kunze, J., Helge, H., & Nau, H. (1983) · PubMed · Cited by 54
Schulz, H.-U., Schürer, M., Bässler, D., & Weiser, D. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1296905 · Cited by 52
Benson, E. A., Eadon, M. T., Desta, Z., Liu, Y., Lin, H., Burgess, K., Segar, M. W., Gaedigk, A., & Skaar, T. C. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00111 · Cited by 47
Tian, X., Swift, B., Zamek‐Gliszczynski, M. J., Belinsky, M. G., Kruh, G. D., & Brouwer, K. L. R. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019273 · Cited by 46
Clinically Relevant Multidrug Transporters Are Regulated by microRNAs along the Human Intestine
Bruckmueller, H., Martin, P. D., Kaehler, M., Haenisch, S., Ostrowski, M., Droździk, M., Siegmund, W., Cascorbi, I., & Oswald, S. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00076 · Cited by 41
Interaction Between Digoxin and Propafenone
Calvo, M. V. M., Martín‐Suárez, A., Luengo, C. M., Avila, C., Cascón, M., & Hurlé, A. (1989) · Therapeutic Drug Monitoring · doi:10.1097/00007691-198901000-00003 · Cited by 38
Schonhoff, C. M., Webster, C. R. L., & Anwer, S. M. (2013) · Hepatology · doi:10.1002/hep.26333 · Cited by 32
Role of Hepatic Drug Transporters in Drug Development
Liu, H., & Sahi, J. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.703 · Cited by 32
Population Pharmacokinetics of Talazoparib in Patients With Advanced Cancer
Yu, Y., Durairaj, C., Shi, H., & Wang, D. D. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1520 · Cited by 31
Self-citationDose-Dependent Targeted Suppression of P-glycoprotein Expression and Function in Caco-2 Cells
Lee, S. D., Osei-Twum, J.-A., & Wasan, K. M. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300668e · Cited by 28
Moj, D., Maas, H. J., Schaeftlein, A., Hanke, N., Gómez‐Mantilla, J. D., & Lehr, T. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00776-y · Cited by 28
One Daily Dose of Diphenylhydantoin for Patients with Epilepsy
Strandjord, R. E., & Johannessen, S. I. (1974) · Epilepsia · doi:10.1111/j.1528-1157.1974.tb04011.x · Cited by 19
Chan, K. K. H., Sawchuk, R. J., Thompson, T. A., Redalieu, E., Wagner, W. E., LeSher, A. R., Weeks, B. J., Hall, N., & Gérardin, A. (1985) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600740813 · Cited by 19
Swift, B., Tian, X., & Brouwer, K. L. R. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9909-z · Cited by 18
Multimodal analysis of drug transporter expression in gastrointestinal tissue
Thompson, C. G., Fallon, J. K., Mathews, M. M., Charlins, P., Remling‐Mulder, L., Kovářová, M., Adamson, L., Srinivas, N., Schauer, A. P., Sykes, C., et al. (2017) · AIDS · doi:10.1097/qad.0000000000001554 · Cited by 17
Renal Excretion of Dabigatran: The Potential Role of Multidrug and Toxin Extrusion (MATE) Proteins
Shen, H., Yao, M., Sinz, M., Marathe, P., Rodrigues, A. D., & Zhu, M. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00472 · Cited by 17
P-gp Induction by Curcumin: An Effective Antidotal Pathway
Wan-Hua, T. J. Y. (2013) · Journal of Bioequivalence & Bioavailability · doi:10.4172/jbb.1000165 · Cited by 16
Cited by
Lee, M.-K. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030264 · Cited by 335
Metadata
- Authors
- Elmeliegy, M., Vourvahis, M., Guo, C., & Wang, D. D.
- Venue
- Clinical Pharmacokinetics
- Published
- 2020-02-13
- Volume
- 59
- Issue
- 6
- Pages
- 699-714
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- OpenAlex
- W3005539395
- Cited by
- 323
- References
- 104
- FWCI
- 13.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.